Refine by
Patient Recruitment Articles & Analysis
70 news found
Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), the leading autologous (patient’s own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce additions to ...
The antibody was transferred to Aulos Bioscience, a Biolojic spinoff that is now conducting clinical trials in Australia and is currently recruiting patients, with hopes of reporting interim data later this year. ...
The implementation of AIR will aid in the recruitment of patients for clinical trials focused on inflammatory bowel disease (IBD). ...
As clinical trial success relies on effective patient recruitment, BioMark is delighted to announced today that enrollment for its pivotal lung cancer screening study exceeded 1000 participants in less than one year. ...
“Antengene believes that cancer treatments involving the rational combination of immuno-oncology drugs and targeted therapies may offer the greatest opportunity for substantial advances in treatment outcomes for patients with cancer,” said Dr. Amily Zhang, Antengene's Chief Medical Officer. ...
XF-73 Nasal targeting peak sales potential of $1 billion in its major target markets Phase 3 patient recruitment could start in 2024 subject to completing an XF-73 Nasal partnering deal in 2023 XF-73 Nasal is the lead drug candidate developed from Destiny Pharma’s XF platform and it is initially being developed for the prevention of post-surgical ...
Electronic Patient-Reported Outcome Measures (ePROMs) are now allowing these patients to self-report health conditions and treatment effectiveness remotely. This is paving the way for improving patient care as ePROMs can be used to monitor patients with reported health conditions coming directly from the patient, ...
The purpose is to bring new and promising medicines to patients sooner. The Fast Track designation enables ITM to have more frequent interactions with the FDA to discuss the ITM-11 development path. ...
Geneva, Switzerland – October 26th, 2022, STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), today announced first patient visits in its new STA-B-001 clinical observational-biosampling study in Spain and USA. ...
BySTALICLA
In this new chapter, Iterative Health will continue to focus on its core products, AI Recruitment, SKOUT™, and AI Documentation. AI Recruitment (AI-R) addresses clinical trial recruitment pain points for pharmaceutical companies and clinical research teams working to surface eligible patients for inflammatory bowel disease ...
Raza, who wrote the best-selling book “The First Cell and the Human Costs of Pursuing Cancer to the Last,” said: “New non-invasive tests are needed to detect the first leukemic cells in the blood of MDS patients so that we can identify and treat patients at risk of developing AML before the disease becomes established.” Patrizia ...
LOS ANGELES, CA – October 6, 2022 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are open to recruit patients for the treatment of Kita-Kyushu lung cancer antigen 1 ...
The clinical trial, started in July 2022 and plans to recruit 50 patients eligible for immediate breast reconstruction in 8 centers in Europe. ...
While no significant differences were observed between the groups, average values of HbA1c at baseline, 5 months, and 12 months were lower in patients with HLA DR3-DQ2 compared to the patients lacking HLA DR3-DQ2. ...
Ondine Biomedical Inc. (LON: OBI), has recruited the final patient to its nasal photodisinfection exploratory Phase 2 trial. ...
About the GADinLADA trial The main aim of the trial was to evaluate the safety of three intralymphatic injections of Diamyd® in patients with LADA (Latent Autoimmune Diabetes in Adults). The patients were recruited in Norway at the Norwegian University of Science and Technology (NTNU), Dept. of Clinical and Molecular Medicine, in Trondheim, ...
Gesynta Pharma AB today announces that all patients have been recruited for the company's clinical Phase II study with the drug candidate GS-248, which is being evaluated as a treatment for the rare disorder systemic sclerosis.The study is intended to demonstrate proof-of-concept and to evaluate the safety profile of GS-248. ...
“The GADinLADA trial has been successful, and treatment with three intralymphatic injections of Diamyd has been well received by the LADA patients,“ says PhD Ingrid K Hals, Sponsor’s representative of the trial. ...
Ariana Pharma and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Ariana Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have the potential to expand personalized cancer ...
If successful, NRTX-1001 cell therapy will provide patients a non-destructive option for the treatment of their seizures.” Cory R. ...